BR9815642A - Vetor sequência de dna mutante, transcrição linear de rna de um vetor, composição e método para produzir uma vacina de rna de vìrus sincicial respiratório - Google Patents

Vetor sequência de dna mutante, transcrição linear de rna de um vetor, composição e método para produzir uma vacina de rna de vìrus sincicial respiratório

Info

Publication number
BR9815642A
BR9815642A BR9815642-0A BR9815642A BR9815642A BR 9815642 A BR9815642 A BR 9815642A BR 9815642 A BR9815642 A BR 9815642A BR 9815642 A BR9815642 A BR 9815642A
Authority
BR
Brazil
Prior art keywords
vector
rna
dna sequence
respiratory syncytial
syncytial virus
Prior art date
Application number
BR9815642-0A
Other languages
English (en)
Other versions
BR9815642B1 (pt
Inventor
Mark Parrington
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of BR9815642A publication Critical patent/BR9815642A/pt
Publication of BR9815642B1 publication Critical patent/BR9815642B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"VETOR, SEQuêNCIA DE DNA MUTANTE, TRANSCRIçãO LINEAR DE RNA DE UM VETOR, COMPOSIçãO E MéTODO PARA PRODUZIR UMA VACINA DE RNA DE VìRUS SINCICIAL RESPIRATóRIO". Um vetor compreendendo uma primeira seq³ência de DNA que é complementar a pelo menos uma parte de um genoma RNA alfavírus e tendo complementos de regiões de replicação completa de genomas RNA alfavírus, uma segunda seq³ência de DNA codificando uma proteína paramyxovirus, particularmente uma proteína de fusão (RSV F) de vírus sincicial respiratório ou um fragmento de proteína RSV F que gera anticorpos que reagem especificamente com proteínas RSV F, a primeira e segunda seq³ências de DNA estando sob o controle transcripcional de um promotor são descritos. Tal vetor pode ser usado para produzir uma transcrição de RNA que pode ser usado para imunizar um hospedeiro, incluindo um hospedeiro humano, para proteger o hospedeiro de doenças causadas por paramyxovirus, particularmente vírus sincicial respiratório, por administração ao hospedeiro. A transcrição de RNA pode ser formada por linearização do vetor através da clivagem em um único sítio de restrição em um vetor plasmídeo e depois transcrição da molécula linear.
BRPI9815642-0B1A 1997-09-04 1998-09-03 vetor sequÊncia de dna mutante, transcriÇço linear de rna de um vetor, composiÇço e mÉtodo para produzir uma vacina de rna de vÍrus sincicial respiratàrio BR9815642B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/923,558 US6060308A (en) 1997-09-04 1997-09-04 RNA respiratory syncytial virus vaccines
PCT/CA1998/000840 WO1999011808A1 (en) 1997-09-04 1998-09-03 Rna respiratory syncytial virus vaccines

Publications (2)

Publication Number Publication Date
BR9815642A true BR9815642A (pt) 2002-12-31
BR9815642B1 BR9815642B1 (pt) 2013-09-17

Family

ID=25448878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9815642-0B1A BR9815642B1 (pt) 1997-09-04 1998-09-03 vetor sequÊncia de dna mutante, transcriÇço linear de rna de um vetor, composiÇço e mÉtodo para produzir uma vacina de rna de vÍrus sincicial respiratàrio

Country Status (9)

Country Link
US (2) US6060308A (pt)
EP (1) EP1009846B1 (pt)
JP (1) JP2001514857A (pt)
AT (1) ATE361368T1 (pt)
AU (1) AU742046B2 (pt)
BR (1) BR9815642B1 (pt)
CA (1) CA2301891C (pt)
DE (1) DE69837708T2 (pt)
WO (1) WO1999011808A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US7465574B2 (en) * 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
US6830748B1 (en) * 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
EP1707633A1 (en) * 1997-11-14 2006-10-04 Sanofi Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
JP2002512003A (ja) * 1997-11-14 2002-04-23 コノート ラボラトリーズ リミテッド パラミキソウイルスワクチンのためのアルファウイルスベクター
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DE60135983D1 (de) 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
KR100481879B1 (ko) * 2001-02-08 2005-04-11 크레아젠 주식회사 (+)-단일쇄 ｒｎａ 재조합 벡터내 삽입 서열의 유전적 안정성을 증가시키는 방법
EP1766034B1 (en) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
EP3115060A1 (en) * 2008-04-18 2017-01-11 VaxInnate Corporation Deletion mutants of flagellin and methods of use
US20120093855A1 (en) * 2008-11-18 2012-04-19 Ligocyte Pharmaceuticals, Inc. RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF
MA33449B1 (fr) * 2009-06-24 2012-07-03 Glaxosmithkline Biolog Sa Antigènes recombinants du vrs
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
DK2591114T3 (en) 2010-07-06 2016-08-29 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
SI4005592T1 (sl) 2010-07-06 2023-03-31 Glaxosmithkline Biologicals S.A. Virionom podobni dostavni delci za samopodvojene molekule RNA
DK2611461T3 (da) 2010-08-31 2022-05-16 Glaxosmithkline Biologicals Sa Pegylerede liposomer til afgivelse af RNA, der koder immunogen
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
JP2014519819A (ja) 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
CN111671918A (zh) 2011-06-08 2020-09-18 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010405A1 (en) 1988-04-22 1989-11-02 The Upjohn Company Chimeric glycoproteins containig immunogenic segments of human parainfluenza virus type 3
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
WO1996017072A2 (en) * 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5614372A (en) * 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines

Also Published As

Publication number Publication date
EP1009846A1 (en) 2000-06-21
WO1999011808A1 (en) 1999-03-11
JP2001514857A (ja) 2001-09-18
ATE361368T1 (de) 2007-05-15
CA2301891A1 (en) 1999-03-11
AU742046B2 (en) 2001-12-13
DE69837708T2 (de) 2008-01-10
BR9815642B1 (pt) 2013-09-17
DE69837708D1 (de) 2007-06-14
AU9056998A (en) 1999-03-22
US6428324B1 (en) 2002-08-06
EP1009846B1 (en) 2007-05-02
CA2301891C (en) 2010-01-19
US6060308A (en) 2000-05-09

Similar Documents

Publication Publication Date Title
BR9815642A (pt) Vetor sequência de dna mutante, transcrição linear de rna de um vetor, composição e método para produzir uma vacina de rna de vìrus sincicial respiratório
Kong et al. Alternative translation initiation site in the DA strain of Theiler's murine encephalomyelitis virus
Paterson et al. Efficient translation of prokaryotic mRNAs in a eukaryotic cell-free system requires addition of a cap structure
DK1056873T3 (da) Fremgangsmåder til produktion af et polypeptid i en Bacillus-celle
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
MX9602993A (es) Hormona del crecimiento humano.
CA2196555A1 (en) Vr-2332 viral nucleotide sequence and methods of use
CY1106806T1 (el) Dna και πολυπεπτιδια ανθρωπινης tslp
JP2004511201A5 (pt)
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
TR200401186T4 (tr) Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
ZA200508666B (en) Insertion of furin protease cleavage sites in membrane proteins and uses thereof
WO2017132332A1 (en) Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes
US12083174B2 (en) Immunogenic compositions and uses thereof
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
Rosenberg et al. Efficient cap-dependent translation of polycistronic prokaryotic mRNAs is restricted to the first gene in the operon
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
DE69836520D1 (de) Clostridium perfringens Impfstoff
CA2195090A1 (en) Lkp pilin structural genes and operon of nontypable haemophilus influenzae
US20160228531A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
KR850001286A (ko) 개량 플라스미드 벡타의 제조방법
RU98112608A (ru) Иммуногенная композиция [на основе] tlp
BR9508645A (pt) Vacina da peritonite infecciosa felina

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6,7 E 8A ANUIDADES

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)